AE37: a novel T-cell-eliciting vaccine for breast cancer

Comparison of different HER2/neuvaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

(2011) Linda C Benavides et al.   Expert Review of Vaccines

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine

(2010) Jarrod P. Holmes et al.   CANCER

Results from a Phase I Clinical Study of the Novel Ii-Key/HER-2/neu(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

(2010) S. A. Perez et al.   CLINICAL CANCER RESEARCH

HER-2/neu as a target for cancer vaccines

(2010) Constantin N Baxevanis et al.   Immunotherapy

HER-2/neu Expression in Prostate Adenocarcinoma: A Systematic Review and Meta-Analysis

(2010) Ary Serpa Neto et al.   JOURNAL OF UROLOGY

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

(2010) Jeremy D. Gates et al.   VACCINE

Results of the first phase 1 clinical trial of the HER-2/neupeptide (GP2) vaccine in disease-free breast cancer patients

(2009) Mark G. Carmichael et al.   CANCER

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2009) L. C. Benavides et al.   CLINICAL CANCER RESEARCH

Use of monoclonal antibodies in the treatment of ovarian cancer

(2009) Seiji Mabuchi et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

FOXP3 Expression and Overall Survival in Breast Cancer

(2009) Andrea Merlo et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

(2008) G. E. Peoples et al.   CLINICAL CANCER RESEARCH

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neuPeptide (AE37) Vaccine

(2008) Jarrod P. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY